| Similar Articles |
|---|
 |
Bio-IT World
March 2006 |
Special Show Preview: It's Showtime! Highlights of the upcoming fifth annual Bio IT World conference: Decoding the Genome... The Six-Figure Sequence... E-Clinical Futures... etc.   |
Bio-IT World
March 8, 2005 |
Coming Attractions Ten reasons why you can't miss the Bio*IT World Conference + Expo in May. Headlines and Legends... Advances in Genomic Medicine... IT Solutions for Drug Discovery... etc. |
Bio-IT World
February 2007 |
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. |
Bio-IT World
February 18, 2004 |
It's Showtime! The 2004 Bio*IT World Conference + Expo promises to be our most exceptional event yet. |
Bio-IT World
August 2005 |
Best Practices 2005 Winners Winners of the Best Practices awards include an innovative drug safety monitoring system, an integrated genomics gateway, and a genotyping pipeline. |
Bio-IT World
September 2005
Mark D. Uehling |
Kings of Genes and Data The speed by which things move at Iceland's deCODE supports the company's claim that it is not only reconnecting the bifurcated worlds of drug discovery and clinical research - it is also internally cross-pollinating ideas between those two realms. |
Bio-IT World
August 2005 |
Project Summaries Summaries of candidates for Bio-IT World's "Best Practices 2005" projects. |
Bio-IT World
Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. |
Bio-IT World
May 2006
Kevin Davies |
Decoding the Genetics of Common Disease Icelandic biopharma deCODE Genetics' Kari Stefansson says his company's search for genes underlying common diseases is not only pushing promising new drug candidates into the clinic but also revealing new insights into the very basis of common disease. |
Bio-IT World
October 2005
Salvatore Salamone |
Masters of the Semantic Web The Semantic Web is just at its early stage of deployment. As with the original Web, the usefulness of a Semantic Web will grow as more data and sites support RDF and the other Semantic Web standards. |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
Bio-IT World
May 2006
Kevin Davies |
Personalized Medicine's Rosy Picture GlaxoSmithKline's head of genetics research, Allen Roses, says that pharmacogenetics is having a profound impact on the stratifying of patients, the minimization of adverse events, and the expedited passage of drug candidates through clinical trials. |
Bio-IT World
November 12, 2002
Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? |
Bio-IT World
August 13, 2002
Mark D. Uehling |
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? |
Bio-IT World
November 2006
Kevin Davies |
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights. |
Bio-IT World
May 9, 2003
Mark D. Uehling |
Data Rapture? Electronic capture of data: Some say it unclogs the medieval clinical trials process. Others remain skeptical of software and put their trust in paper. |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
InternetNews
January 23, 2004
Michael Singer |
Oracle Makes a Play for Life Sciences The business software giant acquires SiteWorks Solutions to capitalize on drug companies that need to run clinical trials. |
Bio-IT World
June 2006
Kevin Davies |
The Data Deluge: Deal or No Deal? Far from decrying the data glut, researchers should embrace the complexity of genomic and other sources of data, particularly for its predictive properties in the field of personalized medicine. |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
Bio-IT World
September 2005
Kevin Davies |
Bringing Good Things to Informatics In interview with Nick Giannasi, Head of Informatics for GE Healthcare's Bio-Sciences division on how the company is shedding light on data integration in discovery and clinical trials. |
Bio-IT World
September 9, 2002
Malorye Branca |
The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
Bio-IT World
February 18, 2004 |
On the Up and Up Market values for biotec companies increase as they deal and deliver in the fourth quarter |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Bio-IT World
November 14, 2003
Hoffer et al. |
Over the Rainbow Yet? Consolidation slows, valuations grow, and now there's hope for some biotech IPOs. |
Bio-IT World
November 2005 |
Bridges and Boundaries in Drug Discovery Research Good communication, blurring cultural boundaries, and strong project governance may be as, if not more, important as sweeping technology solutions when it comes to converging discovery and IT and expediting drug development. |
Bio-IT World
April 2006
John Russell |
Pfizer's Pursuit of Technology Can this $50-billion-plus, 115,000-employee behemoth succeed where other pharma giants have failed and successfully institutionalize the effort to find and develop critical new technology? Should it even try? |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
Pharmaceutical Executive
June 1, 2006
Jill Wechsler |
Washington Report: Promises to Keep Congress wants pharma to meet study commitments and disclose research results, but no one is giving FDA more resources to enforce its rules. |
The Motley Fool
March 18, 2008
Brian Orelli |
The Nuts and Bolts of Drug Research Merck just released a pair of papers detailing the network of proteins that are linked to obesity, but the pharmaceutical company won't benefit much financially from its studies. So who will? |
Pharmaceutical Executive
October 1, 2005
Lisa Grimes |
Clear Road Ahead An industry standard for publicizing clinical-trial results is a ways off. But pharma's openness to more transparent procedures is moving things in the right direction. |
Pharmaceutical Executive
November 1, 2011
Elizabeth O. Coulton |
Clinical Trial Issues Not Just Black and White The selection of clinical trial participants must meld with the changing demographics of America if industry is to improve medicines that work for patients. |
Bio-IT World
February 18, 2004 |
The Quest for Complex Genes Genetic sleuths are homing in on genes for complex diseases with the help of new, and some not so new, tools and strategies. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
Pharmaceutical Executive
June 1, 2013
Ben Comer |
From Locked Box to Data Sphere Project Data Sphere aims to liberate clinical trial data sets from industry and academic vaults, in an attempt to catalyze cancer research and discovery. |
Bio-IT World
March 10, 2003
Spink & Blumenstiel |
Getting IT Right Applying information technology to trials can boost productivity. Here's a strategic framework for going e-clinical. |
The Motley Fool
December 8, 2004
Alyce Lomax |
Eli Lilly Bares All The pharmaceutical publishes clinical trial results online. This is a step toward generating trust -- after all, shareholders, physicians, and consumers alike are likely looking askew at Big Pharma these days. |
Bio-IT World
February 2006
Mark D. Uehling |
Pharma's Mixed Response to Trials Database A late December New England Journal of Medicine article detailed Big Pharma's response to mandatory registration of clinical trials. Here are some highlights. |
Pharmaceutical Executive
September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
Bio-IT World
August 2005
Kevin Davies |
Special Report: Bio-IT World Best Practices 2005 Each year, the Best Practices awards program spotlights examples of the most outstanding innovations, technologies, and practices in the drug discovery pipeline. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Bio-IT World
August 13, 2003
John Rhodes |
Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert. |
Chemistry World
November 12, 2013
Dinsa Sachan |
Rough patch for India's clinical trial industry The Indian clinical trial industry is beset by uncertainty. Campaigners have petitioned the courts claiming that drug companies are exploiting poor people and this has led to more than 100 trials being put on hold. |
The Motley Fool
October 5, 2010
Brian Orelli |
You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
Bio-IT World
March 17, 2004 |
Pharma's Genomic Harvest How Pfizer plans to meet its goal of 20 new drug applications by 2006. |
Bio-IT World
May 2006
Catherine Varmazis |
Spearheading the Semantic Web Several prominent leaders of the Semantic Web movement shared their passion for it at recent Bio-IT World Life Sciences Conference. |
Pharmaceutical Executive
September 1, 2008
Melanie North |
Publish or Perish FDAAA means that companies need to register clinical trials; and not only for publication planning. |
